Safety and immunologic effects of IL-15 administration in nonhuman primates
Open Access
- 17 September 2009
- journal article
- Published by American Society of Hematology in Blood
- Vol. 114 (12), 2417-2426
- https://doi.org/10.1182/blood-2008-12-189266
Abstract
The administration of cytokines that modulate endogenous or transferred T-cell immunity could improve current approaches to clinical immunotherapy. IKeywords
This publication has 51 references indexed in Scilit:
- Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with VaccinesClinical Cancer Research, 2008
- IL‐15 acts as a potent inducer of CD4+CD25hi cells expressing FOXP3European Journal of Immunology, 2008
- IL-15 as a mediator of CD4 + help for CD8 + T cell longevity and avoidance of TRAIL-mediated apoptosisProceedings of the National Academy of Sciences of the United States of America, 2008
- Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primatesJCI Insight, 2008
- IL-2 and IL-15 Each Mediate De Novo Induction of FOXP3 Expression in Human Tumor Antigen-specific CD8 T CellsJournal of Immunotherapy, 2007
- The IL-15/IL-15Rα on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine designNature Reviews Immunology, 2006
- IL-15 induces CD4+ effector memory T cell production and tissue emigration in nonhuman primatesJCI Insight, 2006
- Contributions of CD4+, CD8+, and CD4+CD8+ T cells to skewing within the peripheral T cell receptor β chain repertoire of healthy macaquesHuman Immunology, 1999
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerThe New England Journal of Medicine, 1985